HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Florio, T. Articles by Jaquet, P. Search for Related Content PubMed PubMed Citation Articles by Florio, T. Articles by Jaquet, P.

Departments of¹ Oncology, Biology and Genetics² Neurology, Ophthalmology and Genetics, University of Genova, Viale Benedetto XV, 2, 16132 Genova, Italy³ Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands⁴ Department of Endocrinology, Max Planck Institute of Psychiatry, Munich, Germany⁵ IPSEN, Milford, Massachusetts 01757, USA⁶ Departments of Endocrinology, Neurosurgery, University of Mediterranea, Marseilles, France

(Correspondence should be addressed to T Florio; Email: tullio.florio{at}unige.it)

Dopamine D2 and somatostatin receptors (sstrs) were reported to affect non-functioning pituitary adenoma (NFPA) proliferation in vitro. However, the reported results differ according to the experimental conditions used. We established an experimental protocol allowing reproducible evaluation of NFPA cell proliferation in vitro, to test and compare the antiproliferative effects of dopamine and somatostatin analogs (alone or in combination) with the activity of the dopamine–somatostatin chimeric molecule BIM-23A760. The protocol was utilized by four independent laboratories, studying 38 fibroblast-deprived NFPA cell cultures. Cells were characterized for GH, POMC, sstr1–sstr5, total dopamine D2 receptor (D2R) (in all cases), and D2 receptor long and short isoforms (in 15 out of 38 cases) mRNA expression and for -subunit, LH, and FSH release. D2R, sstr3, and sstr2 mRNAs were consistently observed, with the dominant expression of D2R (2.9±2.6 copy/copy β-glucuronidase; mean±S.E.M.), when compared with sstr3 and sstr2 (0.6±1.0 and 0.3±0.6 respectively). BIM-23A760, a molecule with high affinity for D2R and sstr2, significantly inhibited [³H]thymidine incorporation in 23 out of 38 (60%) NFPA cultures (EC₅₀=1.2 pM and E_max=–33.6±3.7%). BIM-23A760 effects were similar to those induced by the selective D2R agonist cabergoline that showed a statistically significant inhibition in 18 out of 27 tumors (compared with a significant inhibition obtained in 17 out of 27 tumors using BIM-23A760, in the same subgroup of adenomas analyzed), while octreotide was effective in 13 out of 27 cases. In conclusion, superimposable data generated in four independent laboratories using a standardized protocol demonstrate that, in vitro, chimeric dopamine/sstr agonists are effective in inhibiting cell proliferation in two-thirds of NFPAs.

This article has been cited by other articles:

				A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, and S. Savastano Medical therapy for clinically non-functioning pituitary adenomas Endocr. Relat. Cancer, December 1, 2008; 15(4): 905 - 915. [Abstract] [Full Text] [PDF]

				F. Barbieri, A. Bajetto, R. Stumm, A. Pattarozzi, C. Porcile, G. Zona, A. Dorcaratto, J.-L. Ravetti, F. Minuto, R. Spaziante, et al. Overexpression of Stromal Cell-Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas Clin. Cancer Res., August 15, 2008; 14(16): 5022 - 5032. [Abstract] [Full Text] [PDF]